RBC Capital analyst Mike Dahl raised the price target on Taylor Morrison Home (NYSE: TMHC) to $72.50 (from $69.00) while maintaining a Outperform rating.

The analyst comments "• The Deal : The $72.50/share price represents ~1.3x current P/TBV, ~1.2x on RBCe YE'26, and ~1.1x RBCe YE'27. This comes at a slight premium to RBCe's prior $69 PT which was based on a ~1.1x YE'26 TBV (implying ~1.0x YE'27 TBV), with the price representing a ~24% premium to TMHC's Friday closing price of $58.50 (which represented 1.0x current TBV/0.9x YE’26 TBV) and an equivalent to the company's 52-week high (achieved on 9/5/25). We see the multiple as reasonable for TMHC given murkiness in the NT macro and TMHC profitability/ROE (we est. ~HSD% ROE in '26/'27), while strategically offering a stronger LT funding/growth path/ consolidation opp. outside of the public markets. This compares to our current coverage peer group avg. of 1.4x current TBV/1.3x YE’26 TBV/1.2x YE’27 TBV (1.6x/1.5x/1.4x on a cap-wtd. basis) though we note small/ mid-cap builders have largely traded at notable discounts. TMHC has traded at an avg. of 1.2x TBV since its 2013 IPO. We also note recent similar deal comps of TPH (bought by Sumitomo for 1.3x then-current TBV, 1.2x final RBCe FY’26 TBV, 1.1x final RBCe FY’27 TBV) and MDC (bought by Sekisui in 1/24 for 1.5x then-current TBV, 1.3x consensus FY’24 TBV, 1.2x consensus FY’25 TBV). • Interloper/antitrust risk low : We’ve believed TMHC screened as a clear eventual takeout candidate given its balanced buyer segmentation (incl. its active-adult expansion), healthy land position, and inexpensive valuation, though we viewed the growing Japanese-backed platforms as potential buyers. We still believe there theoretically could be other interested bidders including the Japanese, but with this announcement on the tape, we don't see a bidding war as likely or expect a competing bid to offer a greater premium in the current pressured housing environment. We also do not expect any meaningful antitrust or deal approval issues given the relative size (the DOJ recently approved Sumitomo/TPH which created a top-5 US homebuilder) and still heavily fragmented nature of the homebuilding industry. We note a combined Clayton/TMHC does not produce any new, incremental local mkt. shares >20% in the top 50 mkts (see p.3-4). Recall the TPH deal was announced on 2/13 with antitrust clearance on 4/17 and deal closure on 5/14. Strategy & read-throughs : The press release notes CEO Sheryl Palmer and the TMHC management team are expected to stay on and run the company as it transitions private/within BRK's portfolio, though also suggests an eventual 'unification' down the line within the BRK site-built businesses. Our sense is TMHC is relatively complementary to Clayton’s existing site-built platform, and we est. that a total combined BRK SF platform (Clayton/TMHC) generated ~23k closings with ~$12 BN of HB revenue in FY'25, making it the #4 pro-forma builder in the US. This is in addition to Calyton’s separate dominant #1 manufactured housing platform, and we’d also note BRK's recent investments in LEN common stock, all of which reflect an increased focus on housing within the BRK platform. This deal is especially notable given Berkshire’s involvement but marks the 3rd major public homebuilder bid of the year (TPH/ Sumitomo, DFH/BZH) in addition to some regional private builder deals and adds further fuel to the fire of consolidation within the homebuilding industry as an ongoing narrative. We expect this to be viewed as a positive for builders trading at/below 1x TBV, and BRK’s involvement may lift the space more broadly, but the modest takeout premium is less constructive for larger peers already commanding significant premium TBV multiples (DHI, LEN, PHM, TOL)"